Table 2.
A summary of the receptors involved in activating JAK/STAT pathway in cancer.
| Receptors | Cancer type* | Activated JAK | Activated STAT | References | |
|---|---|---|---|---|---|
| G protein-coupled receptors (GPCR) | 5-HT2AR | Breast | JAK2 | STAT3 | (61) |
| CCR 2 | Squamous cell | JAK2 | STAT3 | (62) | |
| CCR 5 | Breast | JAK1 | STAT5 | (62) | |
| CXCR4 | GI; Breast | JAK2,3 | STAT1,2,3,5 | (63) | |
| PAFR | Breast; Hepatocellular | JAK2; TYK2 | STAT1,2,3,5 | (64), (65) | |
| PAR 1 | Breast | JAK2 | STAT1,3 | (66) | |
| BDKRB2 (B2R) | Ovarian; Pancreatic | TYK2 | STAT3 | (67) | |
| AT1 R | breast | JAK2; TYK2 | STAT1,2,3,5 | (68), (69) | |
| Cytokine receptors | IL-2 R | Glioma; Breast | JAK1,2,3 | STAT1,3,4,5 | (70), (71) |
| IL-3 R | Hematologic | JAK1,2 | STAT5 | (72) | |
| IL-4 R | Cervical; Ovarian; Liver | JAK1,3 | STAT6 | (73) | |
| IL-5 R | Leukemia | JAK1,2 | STAT1,5 | (74), (75) | |
| IL-6 R | Breast | JAK1,2; TYK2 | STAT1,3 | (73), (76) | |
| IL-7 R | Multiple Types | JAK1,3 | STAT1,3,5 | (77), (78) | |
| IL-9 R | Ovarian; Pancreatic | JAK1,3 | STAT1,3,5 | (79), (80) | |
| IL-10 R (α & β) | Multiple Types | JAK1; TYK2 | STAT1,3 | (73), (81) | |
| IL-11 R | Breast; Prostate | JAK1,2 | STAT1,3 | (82) | |
| IL-12 R | Ovarian; Melanoma | JAK2; TYK2 | STAT1,3,4,5 | (83) | |
| IL-13 R | Multiple Types | JAK1,2; TYK2 | STAT1,3,5,6 | (84) | |
| IL-15 R | Colorectal | JAK1,3 | STAT3,5 | (76) | |
| IL-20 R | Multiple Types | JAK1 | STAT1,3 | (85) | |
| IL-21 R | Multiple Types | JAK1,3 | STAT1,3,5 | (86) | |
| IL-22 R | Colorectal | JAK1; TYK2 | STAT3 | (87) | |
| IL-23 R | Squamous cell carcinoma; Breast | JAK2; TYK2 | STAT1,3,4,5 | (83), (88) | |
| IL-24 R | Multiple Types | JAK1 | STAT3 | (89) | |
| IL-27 R | Multiple Types | JAK1,2; TYK2 | STAT1,2,3,4,5 | (90) | |
| IL-31 R | Lymphoma | JAK1,2 | STAT1,3,5 | (91) | |
| IFN α & β | Multiple Types | JAK1; TYK2 | STAT1,2,3,4,5 | (92) | |
| IFN γ | Multiple Types | JAK1,2 | STAT1,3,5 | (92) | |
| IFNλ (IL28/29) | Multiple Types | JAK1; TYK2 | STAT1,2 | (93) | |
| GM-CSFR | Melanoma | JAK2 | STAT5 | (94) | |
| G-CSFR | Cervical; Thyroid | JAK1,2 | STAT1,3,5 | (95) | |
| Leptin R | Breast | JAK2 | STAT3 | (96) | |
| Receptor tyrosine kinases | EGFR | Multiple Types | JAK1,2 | STAT1,3 | (97) |
| Insulin R | Multiple Types | JAK2 | STAT1 | (98) | |
| FGFR | Multiple Types | JAK2 | STAT1,3 | (99), (100) | |
| PDGFR | Glioma; Breast | JAK2 | STAT1,3,5,6 | (101), (102) | |
| VEGFR | All solid tumors | JAK2 | STAT1,3,5 | (103) | |
| TrkR | Breast Cancer | JAK2 | STAT3 | (104) | |
| TieR | Multiple types | – | STAT1 | (105) | |
| Homodimeric hormone receptors | EPOR | Breast | JAK2 | STAT3,5 | (71) |
| PRLR | Breast | JAK2 | STAT1,3,5 | (106) | |
| GHR | Multiple Types | JAK2 | STAT1,3,5 | (107) | |
| TpoR | Myeloproliferative | JAK2; TYK2 | STAT1,3,5 | (108) | |
*
While the receptors included in the table are obviously expressed in multiple types of cancer, the specified type is related to the reference cited, and the link to the JAK/STAT pathway.